ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.

Alberto A Chiappori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.